1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Dexcel Pharma - Strategic SWOT Analysis Review

Dexcel Pharma - Strategic SWOT Analysis Review

  • March 2016
  • -
  • Global Data
  • -
  • 24 pages

Dexcel Pharma - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Dexcel Pharma (Dexcel) is a pharmaceutical company which develops and markets healthcare products. Its products include Cetirizine, Zyllergy, Alvoran, Betaren, Defanac, Diclofenac, Diclofenac Atid, Aceridex, Aspirin, Cadex, Losartan, Metoprolol Atid, Iomeron, Iopamiro, Periochip, Cemidin, Cimetidine, and Daivobet. Dexcel develops formulations using proprietary, patent-protected, drug delivery technologies. It offers products in the therapeutic areas such as allergy, analgesics, cardiovascular, dental, derma, cosmetics, diabetes, hypertension, digestive, psychiatry, neurology, oncology, infection, and pain relief, among others. The company operates through its subsidiaries such as US, UK and Germany. It also has it manufacturing facilities in Or Akiva, Yokneam and Jerusalem. Dexcel is headquartered in Haifa, Israel.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Dexcel Pharma - Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Section 1 - About the Company 5
Dexcel Pharma - Key Facts 5
Dexcel Pharma - Key Employees 6
Dexcel Pharma - Key Employee Biographies 7
Dexcel Pharma - Major Products and Services 8
Dexcel Pharma - Pharmaceutical Pipeline Products Data 9
Dexcel Pharma, Pipeline Products by Therapy Area 9
Dexcel Pharma, Pipeline Products by Development Phase 10
Dexcel Pharma - History 11
Dexcel Pharma - Company Statement 12
Dexcel Pharma - Locations And Subsidiaries 13
Head Office 13
Other Locations and Subsidiaries 13
Section 2 - Company Analysis 14
Dexcel Pharma - Business Description 14
Dexcel Pharma - Corporate Strategy 15
Dexcel Pharma - SWOT Analysis 16
SWOT Analysis - Overview 16
Dexcel Pharma - Strengths 16
Strength - Patented Technologies Base 16
Strength - Operational Base 16
Dexcel Pharma - Weaknesses 17
Weakness - Reliance on Distributors 17
Dexcel Pharma - Opportunities 18
Opportunity - Increasing Opportunities in Emerging Markets 18
Opportunity - Changing Demographics 18
Dexcel Pharma - Threats 19
Threat - Uncertain RandD Outcomes 19
Threat - Stringent Government Regulations 19
Threat - Competitive Environment 19
Dexcel Pharma - Key Competitors 20
Section 3 - Company's Lifesciences Financial Deals and Alliances 21
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 21
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 22
Dexcel Pharma, Recent Deals Summary 23
Section 4 - Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Dexcel Pharma, Key Facts 5
Dexcel Pharma, Key Employees 6
Dexcel Pharma, Key Employee Biographies 7
Dexcel Pharma, Major Products and Services 8
Dexcel Pharma, Number of Pipeline Products by Therapy Area 9
Dexcel Pharma, Number of Pipeline Products by Development Stage 10
Dexcel Pharma, Pipeline Products By Therapy Area and Development Phase 10
Dexcel Pharma, History 11
Dexcel Pharma, Subsidiaries 13
Dexcel Pharma, Key Competitors 20
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 21
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 22
Dexcel Pharma, Recent Deals Summary 23

List of Figures
Dexcel Pharma, Pipeline Products by Therapy Area 9
Dexcel Pharma, Pipeline Products by Development Phase 10
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 21
Dexcel Pharma, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.